Premium
Japan Society of Obstetrics and Gynecology and Japan Society for Menopause and Women's Health 2017 guidelines for hormone replacement therapy
Author(s) -
Okano Hiroya,
Higuchi Tsuyoshi,
Kurabayashi Takumi,
Makita Kazuya,
Mizunuma Hideki,
Mochizuki Yoshiko,
Obayashi Satoshi,
Yasui Toshiyuki,
Takamatsu Kiyoshi
Publication year - 2018
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.13684
Subject(s) - medicine , hormone replacement therapy (female to male) , interim , menopause , obstetrics and gynaecology , quality of life (healthcare) , gynecology , family medicine , obstetrics , nursing , pregnancy , genetics , archaeology , testosterone (patch) , biology , history
Hormone replacement therapy (HRT) plays a large part in maintaining and improving the quality of life (QOL) of postmenopausal women. Despite this obvious role, the use of HRT has stagnated in Japan as well as the United States, since the interim report of the HRT trial of Women's Health Initiative study was published in 2002. The Japan Society of Obstetrics and Gynecology and Japan Society for Menopause and Women's Health formulated the Guidelines for Hormone Replacement Therapy in 2009, which was subsequently revised in 2012, with the aim of organizing perceptions about HRT and allowing people to provide or receive HRT with a sense of security. Later on, in light of changes in indications for HRT and attitudes toward its impact on cancer risks, amendments were made again in 2017. With the establishment of the 2017 guidelines, practitioners in Japan are able to address various issues related to HRT with more appropriate judgment. Moreover, the practice of reliable, safe and effective HRT is expected to promote further efforts toward improvement or maintenance of QOL in patients.